Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates


Under the terms of the agreement, Samsung Bioepis will be responsible for development, regulatory registration in key markets, and manufacture of the biosimilars, while Sandoz will be responsible for commercialization in global markets, excluding China, Hong Kong, Taiwan, Macau, and Republic of Korea.



Source link

  • Related Posts

    How one Web3 company is investing in the future of the blockchain

    How one Web3 company is investing in the future of the blockchain Source link

    Israeli strike levels building in central Beirut

    IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Israeli strike levels building in central Beirut 00:22 UP NEXT Kalshi accused of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gale of Darkness Gets Nintendo Switch 2 Launch Today

    Gale of Darkness Gets Nintendo Switch 2 Launch Today

    Macy’s Inc. returns to comparable sales growth in Q4

    Macy’s Inc. returns to comparable sales growth in Q4

    EU small parcels tax will not halt flood of Chinese goods, top official warns

    EU small parcels tax will not halt flood of Chinese goods, top official warns

    Chris Selley: Let’s livestream the Canadian justice system — all of it

    Scotland's assisted dying bill rejected after emotional debate

    Scotland's assisted dying bill rejected after emotional debate

    How one Web3 company is investing in the future of the blockchain

    How one Web3 company is investing in the future of the blockchain